Shulman Rogers represented Vigene Biosciences, Inc., a leading biotechnology company for viral vector production and development located in Rockville, Maryland (Vigene), in connection with Vigene’s acquisition of the assets of Omnia Biologics, Inc., another Rockville-based company that offers cGMP production and process development services for gene therapeutics through commercial recombinant proteins (Omnia).
In a press release issued by Vigene on November 29, 2016, Vigene’s Chief Executive Officer, Dr. Zairen Sun, indicated that Vigene is “pleased to have taken this step to expand [its] cGMP capacity and capability,” which he believes “complement[s] the current strong position of Vigene in the viral vector research reagent market.” The assets acquired by Vigene from Omnia included a 7,000 square-foot laboratory space, including three cGMP manufacturing suites and one process development laboratory for viral vector production, including AAV, lentivirus and adenovirus. Vigene also acquired Omnia’s cGMP quality system and personnel qualified for manufacturing clinical grade viral vectors.
The Shulman Rogers M&A team advising Vigene was led by Scott Museles, who was assisted by Keith Marshall. Meredith Campbell advised Vigene on employment matters.
Stay up to date with all the latest news and events.